To evaluate the possibility that inclusion of cisplatin or carboplatin in the chemotherapy had confounded an underlying relationship between CHFR expression and treatment outcome, we also conducted a large PDX study examining the relationship between CHFR expression and response to second-line paclitaxel monotherapy (the setting where paclitaxel is used as a single agent in ovarian cancer). The gene discussed is CHFR; the disease is ovarian cancer.